Cargando…
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia
Leukocyte immunoglobulin (Ig)-like receptor Bs (LILRBs), a family of type I transmembrane glycoproteins, are known to inhibit immune activation. Here, we comprehensively evaluated the molecular, prognostic, and immunological characteristics of LILRB members in a broad spectrum of cancer types, focus...
Autores principales: | Xu, Zi-jun, Zhang, Xin-long, Jin, Ye, Wang, Shi-sen, Gu, Yu, Ma, Ji-chun, Wen, Xiang-mei, Leng, Jia-yan, Mao, Zhen-wei, Lin, Jiang, Qian, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9233190/ https://www.ncbi.nlm.nih.gov/pubmed/35795094 http://dx.doi.org/10.1016/j.omto.2022.05.011 |
Ejemplares similares
-
LILRB4, an immune checkpoint on myeloid cells
por: Yang, Ting, et al.
Publicado: (2022) -
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation
por: Yeboah, Muchaala, et al.
Publicado: (2020) -
Integrated analysis reveals distinct molecular, clinical, and immunological features of B7‐H3 in acute myeloid leukemia
por: Zhang, Ling‐yi, et al.
Publicado: (2021) -
Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia
por: Wen, Xiang-mei, et al.
Publicado: (2021) -
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
por: Zeller, Tobias, et al.
Publicado: (2023)